tiprankstipranks
Advertisement
Advertisement

PHVS Stock Latest News

Buy Rating Reaffirmed as Deucrictibant Advances Toward Key Phase 3 Readout; $52 Price Target Maintained
RatingsBuy Rating Reaffirmed as Deucrictibant Advances Toward Key Phase 3 Readout; $52 Price Target Maintained
9d ago
PHVS
Pharvaris reports Q2 EPS (EUR 0.70) vs. (EUR 0.83) last year
PremiumThe Fly
Pharvaris reports Q2 EPS (EUR 0.70) vs. (EUR 0.83) last year
20d ago
PHVS
Pharvaris price target raised to $75 from $74 at Citizens
PremiumThe Fly
Pharvaris price target raised to $75 from $74 at Citizens
21d ago
PHVS
Pharvaris price target raised to $38 from $35 at BofA
PremiumThe Fly
Pharvaris price target raised to $38 from $35 at BofA
21d ago
PHVS
Pharvaris price target raised to $40 from $39 at Guggenheim
PremiumThe Fly
Pharvaris price target raised to $40 from $39 at Guggenheim
21d ago
PHVS
Pharvaris Posts Q2 2026 Results as Deucrictibant Nears Key Phase 3 Data and Regulatory Milestones
PremiumCompany AnnouncementsPharvaris Posts Q2 2026 Results as Deucrictibant Nears Key Phase 3 Data and Regulatory Milestones
25d ago
6K
PHVS
Pharvaris price target raised to $35 from $33 at BofA
Premium
The Fly
Pharvaris price target raised to $35 from $33 at BofA
1M ago
PHVS
Pharvaris announces publication of review article on bradykinin
Premium
The Fly
Pharvaris announces publication of review article on bradykinin
2M ago
PHVS
IBM downgraded, Cava upgraded: Wall Street’s top analyst calls
PremiumThe Fly
IBM downgraded, Cava upgraded: Wall Street’s top analyst calls
2M ago
AIG
AJG
Pharvaris initiated with an Overweight at Wells Fargo
PremiumThe Fly
Pharvaris initiated with an Overweight at Wells Fargo
2M ago
PHVS
Pharvaris Shareholders Approve 2025 Accounts and Renew Board Authorities at 2026 AGM
PremiumCompany Announcements
Pharvaris Shareholders Approve 2025 Accounts and Renew Board Authorities at 2026 AGM
2M ago
6K
PHVS
Analyst Reiterates Buy on Deucrictibant’s Strong HAE Profile and Lifts Price Target to $46
PremiumRatings
Analyst Reiterates Buy on Deucrictibant’s Strong HAE Profile and Lifts Price Target to $46
2M ago
PHVS
Pharvaris price target raised to $46 from $41 at Morgan Stanley
PremiumThe FlyPharvaris price target raised to $46 from $41 at Morgan Stanley
2M ago
PHVS
Buy Rating Reiterated on Pharvaris with Unchanged $52 Price Target Ahead of Key Phase 3 Deucrictibant XR Readout
Premium
Ratings
Buy Rating Reiterated on Pharvaris with Unchanged $52 Price Target Ahead of Key Phase 3 Deucrictibant XR Readout
3M ago
PHVS
Pharvaris Sets June 26, 2026 AGM as Late-Stage Angioedema Programs Advance
Premium
Company Announcements
Pharvaris Sets June 26, 2026 AGM as Late-Stage Angioedema Programs Advance
3M ago
6K
PHVS
Pharvaris management to meet with Oppenheimer
PremiumThe Fly
Pharvaris management to meet with Oppenheimer
3M ago
PHVS
Pharvaris management to meet with Oppenheimer
PremiumThe Fly
Pharvaris management to meet with Oppenheimer
3M ago
PHVS
Pharvaris Maintained at Buy as Analyst Reaffirms $52 Price Target on Deucrictibant Late-Stage Strength and M&A Optionality
PremiumRatings
Pharvaris Maintained at Buy as Analyst Reaffirms $52 Price Target on Deucrictibant Late-Stage Strength and M&A Optionality
3M ago
PHVS
Pharvaris price target raised to $33 from $31 at BofA
PremiumThe Fly
Pharvaris price target raised to $33 from $31 at BofA
4M ago
PHVS
Pharvaris price target lowered to $74 from $75 at Citizens
PremiumThe FlyPharvaris price target lowered to $74 from $75 at Citizens
4M ago
PHVS
Pharvaris reports Q1 EPS (EUR 0.59) vs. (EUR 0.85) last year
Premium
The Fly
Pharvaris reports Q1 EPS (EUR 0.59) vs. (EUR 0.85) last year
4M ago
PHVS
Pharvaris Extends Cash Runway Into 2028 as Deucrictibant Nears Key Late-Stage Milestones
Premium
Company Announcements
Pharvaris Extends Cash Runway Into 2028 as Deucrictibant Nears Key Late-Stage Milestones
4M ago
6K
PHVS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >